Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudineadefovir combination therapy in patients with lamivudine- resistant chronic hepatitis B
Korean Journal of Hepatology 2014³â 20±Ç 3È£ p.274 ~ p.282
±èÁ¤ÇÑ(Kim Jeong-Han) - Konkuk University School of Medicine Department of Internal Medicine
¹®Èñ¿ø(Moon Hee-Won) - Konkuk University School of Medicine Department of Laboratory Medicine
°í¼ø¿µ(Ko Soon-Young) - Konkuk University School of Medicine Department of Internal Medicine
ÃÖ¿øÇõ(Choe Won-Hyeok) - Konkuk University School of Medicine Department of Internal Medicine
±Ç¼Ò¿µ(Kwon So-Young) - Konkuk University School of Medicine Department of Internal Medicine
Abstract
Background/Aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this study investigated the correlation between HBsAg level and treatment response in LMV- resistant CHB patients treated with adefovir (ADV) add-on therapy.
Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAg levels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed by determining the virological response (VR, undetectable HBV DNA levels) during treatment.
Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline (4.0 vs. 3.6 Log10 IU/mL, p=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VR and became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, p=0.002; 3.8 vs. 3.2 at 1 year, p=0.004; 3.9 vs. 3.2 at 2 years, p=0.008; 3.7 vs. 3.1 at 3 years, p =0.020).
Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.
Å°¿öµå
Hepatitis B, Chronic, Hepatitis B surface antigen, Lamivudine, Adefovir, Resistance
KMID :
1103920140200030274
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)